Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Emerald Health Therapeutics, Inc. - Footnote Information (Details)

v3.22.2.2
Acquisition of Emerald Health Therapeutics, Inc. - Footnote Information (Details)
 9 Months Ended
Nov. 10, 2022
shares
Sep. 30, 2022
USD ($)
agreement
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Asset Acquisition [Line Items]        
Decrease to assets held for sale   $ 0 $ 0  
Decrease to accrued payroll liabilities   (443,983) (443,983) $ (344,450)
Decrease in other current liabilities   (526,818) (526,818) (375,842)
Common stock, $0.001 par value; 5,000,000,000 shares authorized; 912,187,027 shares issued and outstanding at September 30, 2022   $ 495,925 $ 495,925 $ 476,108
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001 $ 0.001
Outstanding shares (in shares) | shares   37,755,000 37,755,000 35,405,000
Grant date fair value   $ 0 $ 0 $ 134,750
Granted (in shares) | shares     4,350,000  
Pro Forma        
Asset Acquisition [Line Items]        
Decrease to assets held for sale   (7,254,576) $ (7,254,576)  
Decrease to accrued payroll liabilities   (1,111,701) (1,111,701)  
Decrease in other current liabilities   (2,366,892) (2,366,892)  
Common stock, $0.001 par value; 5,000,000,000 shares authorized; 912,187,027 shares issued and outstanding at September 30, 2022   $ 912,196 $ 912,196  
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001  
Emerald Health Therapeutics, Inc.        
Asset Acquisition [Line Items]        
Number of shares to be issued per acquiree share (in shares) | shares   0.026    
Common stock   $ 10,823,033    
Convertible securities   428,747    
Transaction costs   1,604,444 $ 1,604,444  
Warrants issued   $ 314,498    
Exchange ratio   1.95 1.95  
Stock options issued   $ 114,249    
Outstanding shares (in shares) | shares   4,247,500 4,247,500  
Number of tranches | agreement   2    
Emerald Health Therapeutics, Inc. | Subsequent Event        
Asset Acquisition [Line Items]        
Number of shares issued (in shares) | shares 416,270,514      
Exchange ratio 1.95      
Emerald Health Therapeutics, Inc. | Director        
Asset Acquisition [Line Items]        
Grant date fair value   $ 82,592 $ 82,592  
Granted (in shares) | shares   2,000,000    
Emerald Health Therapeutics, Inc. | Director | First Tranche        
Asset Acquisition [Line Items]        
Number of tranches | agreement   1    
Emerald Health Therapeutics, Inc. | Pro Forma        
Asset Acquisition [Line Items]        
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001  
Outstanding shares (in shares) | shares   8,282,626 8,282,626  
EHT, Transactions Accounting Adjustments | COO        
Asset Acquisition [Line Items]        
Decrease to accrued payroll liabilities   $ 438,222 $ 438,222  
EHT, Transactions Accounting Adjustments | Director        
Asset Acquisition [Line Items]        
Decrease to accrued payroll liabilities   (78,693) (78,693)  
EHT, Transactions Accounting Adjustments | CEO & CFO        
Asset Acquisition [Line Items]        
Decrease to accrued payroll liabilities   (129,500) (129,500)  
EHT, Transactions Accounting Adjustments | Pro Forma        
Asset Acquisition [Line Items]        
Decrease to assets held for sale   1,849,575 1,849,575  
Decrease to accrued payroll liabilities   (646,415) (646,415)  
Decrease in other current liabilities   (459,548) (459,548)  
Common stock, $0.001 par value; 5,000,000,000 shares authorized; 912,187,027 shares issued and outstanding at September 30, 2022   416,271 416,271  
EHT Transactions Accounting Adjustments, Direct Costs | Pro Forma        
Asset Acquisition [Line Items]        
Decrease to assets held for sale   550,000 550,000  
EHT Transactions Accounting Adjustments, Fair Value | Pro Forma        
Asset Acquisition [Line Items]        
Decrease to assets held for sale   1,299,575 1,299,575  
EHT Transactions Accounting Adjustments, Estimated Transaction Costs | Pro Forma        
Asset Acquisition [Line Items]        
Decrease in other current liabilities   (216,000) (216,000)  
EHT Transactions Accounting Adjustments, Equity Issuance Costs | Pro Forma        
Asset Acquisition [Line Items]        
Decrease in other current liabilities   (50,000) (50,000)  
EHT Transactions Accounting Adjustments, Tail Insurance Policy | Pro Forma        
Asset Acquisition [Line Items]        
Decrease in other current liabilities   $ 193,548 $ 193,548